Two Companies, Two BARDA Contracts, Two Approaches To Coronavirus
Executive Summary
Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.
You may also be interested in...
COVID-19 Vaccine Access Uproar Underscores Importance Of At-Risk Manufacturing
Sanofi CEO Hudson tries to reassure France on access, but notes that Europe does not currently have a program to assure a supply of a coronavirus vaccine as soon as safety and efficacy have been established.
A Downside Of Pandemic Preparedness: Wall Street May Not Value Government Contracts
Human Genome Sciences founder William Haseltine says company's stock did not move following BARDA contract for its anthrax treatment; advises industry to forget about IP for COVID-19 products.
BARDA Shake Up May Prompt Broad Review Of Politicization of Countermeasures Office
Rick Bright is requesting an inspector general investigation into his removal as director of the Biomedical Advanced Research and Development, accusing the Trump administration of favoring politics over science when making COVID-19 funding decisions.